Ovid Therapeutics (OVID)
(Real Time Quote from BATS)
$1.09 USD
-0.02 (-1.80%)
Updated Sep 11, 2024 01:50 PM ET
3-Hold of 5 3
F Value F Growth A Momentum F VGM
Balance Sheet
Fiscal Year End for Ovid Therapeutics falls in the month of December.
All items in Millions except Per Share data.
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 106 | 129 | 188 | 72 | 77 |
Receivables | 0 | 0 | 0 | 0 | 1 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 0 | 0 | 0 | 0 | 0 |
Other Current Assets | 4 | 2 | 3 | 3 | 2 |
Total Current Assets | 110 | 131 | 190 | 75 | 80 |
Net Property & Equipment | 1 | 1 | 0 | 0 | 0 |
Investments & Advances | 18 | 6 | 2 | 0 | 0 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 0 | 0 | 0 | 0 | 0 |
Intangibles | 0 | 0 | 0 | 0 | 0 |
Deposits & Other Assets | 2 | 2 | 2 | 1 | 1 |
Total Assets | 144 | 155 | 195 | 76 | 81 |
Liabilities & Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 4 | 2 | 7 | 5 | 3 |
Current Portion Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | 1 | 1 | 0 | 0 | 0 |
Accrued Expenses | 7 | 5 | 8 | 12 | 7 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 0 | 0 | 0 | 5 | 0 |
Total Current Liabilities | 11 | 7 | 15 | 22 | 11 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 0 | 0 | 0 | 10 | 0 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Non-Current Capital Leases | 15 | 16 | 0 | 0 | 0 |
Other Non-Current Liabilities | 30 | 0 | 0 | 0 | 0 |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 56 | 23 | 15 | 32 | 11 |
Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 0 | 0 | 0 | 0 | 0 |
Capital Surplus | 366 | 358 | 351 | 338 | 283 |
Retained Earnings | -278 | -226 | -171 | -294 | -213 |
Other Equity | 0 | 0 | 0 | 0 | 0 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | 88 | 132 | 180 | 44 | 70 |
Total Liabilities & Shareholder's Equity | 144 | 155 | 195 | 76 | 81 |
Total Common Equity | 88 | 132 | 180 | 44 | 70 |
Shares Outstanding | 70.60 | 70.40 | 68.00 | 63.40 | 47.80 |
Book Value Per Share | 1.24 | 1.88 | 2.64 | 0.69 | 1.46 |
Fiscal Year End for Ovid Therapeutics falls in the month of December.
All items in Millions except Per Share data.
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 77 | 90 | 106 | 87 | 97 |
Receivables | 0 | 0 | 0 | 0 | 0 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 0 | 0 | 0 | 0 | 0 |
Other Current Assets | 4 | 3 | 4 | 5 | 6 |
Total Current Assets | 81 | 93 | 110 | 92 | 102 |
Net Property & Equipment | 1 | 1 | 1 | 1 | 1 |
Investments & Advances | 21 | 22 | 18 | 16 | 16 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 0 | 0 | 0 | 0 | 0 |
Intangibles | 0 | 0 | 0 | 0 | 0 |
Deposits & Other Assets | 2 | 2 | 2 | 2 | 2 |
Total Assets | 118 | 132 | 144 | 125 | 136 |
Liabilities & Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 5 | 4 | 4 | 1 | 4 |
Current Portion Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | 1 | 1 | 1 | 1 | 1 |
Accrued Expenses | 8 | 4 | 7 | 6 | 5 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 0 | 0 | 0 | 0 | 0 |
Total Current Liabilities | 14 | 9 | 11 | 9 | 10 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 0 | 0 | 0 | 0 | 0 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Non-Current Capital Leases | 14 | 14 | 15 | 15 | 15 |
Other Non-Current Liabilities | 1 | 30 | 0 | 0 | |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 29 | 53 | 56 | 24 | 26 |
Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 0 | 0 | 0 | 0 | 0 |
Capital Surplus | 370 | 368 | 366 | 364 | 362 |
Retained Earnings | -281 | -290 | -278 | -263 | -251 |
Other Equity | 0 | 0 | 0 | 0 | 0 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | 89 | 78 | 88 | 101 | 111 |
Total Liabilities & Shareholder's Equity | 118 | 132 | 144 | 125 | 136 |
Total Common Equity | 89 | 78 | 88 | 101 | 111 |
Shares Outstanding | 70.90 | 70.80 | 70.60 | 70.60 | 70.50 |
Book Value Per Share | 1.25 | 1.11 | 1.24 | 1.43 | 1.57 |